AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 53 min read$BMRN

BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect

BioMarin Pharmaceutical (BMRN) will report earnings Thursday after the bell. Last quarter, it posted revenue of $766.2 million, up 2.8% YoY, but missed analysts’ revenue and EPS estimates, while beating full-year EPS guidance. For the upcoming quarter, analysts expect revenue growth of 12.6% YoY. The article cites an average analyst price target of $87.92 versus $59.50.

Original reporting
financialcontent.com
Published Aug 5, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect — source image
Source · financialcontent.com
Decision brief

The 30-second read

$BMRNNeutralMed
01

Why it matters

Traders can use the stated consensus and the company’s recent pattern of revenue estimate misses to frame positioning and implied volatility into the after-hours report.

02

Market read

This is a pre-earnings setup for BMRN with consensus revenue growth and prior-quarter context, not a new disclosure.

03

What to watch

The piece does not discuss product-specific drivers, pipeline updates, or guidance details that typically determine post-earnings repricing.

Relevance 4/10Novelty 4/10Timing: ahead of Thursday after-the-bell earnings

Background

The article previews BioMarin’s upcoming earnings, referencing last quarter’s revenue and EPS performance and the current consensus revenue growth rate.

Company-level read

Ticker impact

$BMRNNeutralMedium confidence
Context

BioMarin is scheduled to report earnings after the bell Thursday, with consensus expecting 12.6% YoY revenue growth.

Expected impact

Likely elevated volatility into the print, with direction dependent on whether revenue and EPS land relative to the cited consensus.

Evidence & confidence

No new guidance, filings, or datapoints are disclosed here. The only actionable element is the timing of the earnings release and the stated consensus expectations.

Market effects

Sector

Peers’ recent results (Biogen, Amgen) are used as a read-across, but the article provides no new sector-wide regulatory or demand shock.

Regional

None specified.

Global

None specified.

Counterpoint

What could challenge this read

If BMRN’s EPS beat last quarter was driven by cost discipline or mix, the stock could outperform even with another revenue miss.

Key entities

  • company
    BioMarin Pharmaceutical

    Subject of the earnings preview, scheduled to report after the bell Thursday.

  • peer
    Biogen

    Peer cited for Q2 revenue growth and beat versus expectations.

  • peer
    Amgen

    Peer cited for Q2 revenue growth and beat versus expectations.

Read at source← All news

Related articles

AUG 6
$BMRNMed

BIOMARIN PHARMACEUTICAL INC (BMRN): Results of Operations and Financial Condition

BIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 earningsrelease-6aug26ex991.htm EX-99.1 Document Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Second Quarter 2026 Financial and Operating Resul

SEC EDGAR 8-K6 min
JUL 13
$BMRNMed

BioMarin Seeks Full FDA Approval For VOXZOGO In Achondroplasia

BioMarin (BMRN) said the FDA accepted its supplemental NDA for VOXZOGO (vosoritide) to seek full approval for children with achondroplasia. The FDA set a PDUFA action date of Feb. 28, 2027. The filing relies on data from three ongoing studies measuring adult height and other growth outcomes. BMRN shares were $59.19, up 0.11% on the day.

rttnews.com2 min
JUN 1
$BMRNMedAI 9/10

BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development

BioMarin Pharmaceutical reported positive Phase 3 results for VOXZOGO in children with hypochondroplasia, meeting the primary endpoint and showing statistically significant improvement in annualized growth velocity, with safety consistent with achondroplasia. The company plans to submit a supplemental NDA to the FDA in Q3 and file with the EMA. H.C. Wainwright reiterated a Neutral rating and set a $50 target.

finance.yahoo.com4 min
MAY 29
$CNCMedAI 8/10

Morgan Stanley says these 'dividend hopefuls' are poised to outperform if they initiate a payout

Morgan Stanley strategist Todd Castagno said companies that initiate regular quarterly dividends have historically outperformed: 650 basis points on average over six months and 1,000 basis points over 12 months after announcements, according to his note. He screened for “dividend hopefuls” with no current quarterly payout, net cash >5% of market cap, and free cash flow yield >5%. Examples: Centene (18% FCF yield), BioMarin (10.4% FCF yield; revenue guidance $3.825–$3.925B), Duolingo (user shortf

cnbc.com6 min
AUG 8
$RIVNMed

What Rivian And Lucid's Latest Earnings Say About The EV Startup Race

The article compares Rivian and Lucid after their 2021 IPOs, focusing on recent earnings. Lucid reported $405 million revenue in the quarter, with net loss widening to over $1 billion, and announced an “operational reset” tied to $1.4 billion cash savings in 2026, plus $3 billion liquidity. Rivian reported $1.66 billion revenue last quarter and raised 2026 delivery guidance to 65,000-70,000 vehicles.

insideevs.com6 min